TNFRSF17 and Miyoshi myopathy: Clinical trials targeting other MM antigen targets such as BCMA, have also shown incredible response rates17–19, however unlike CS1, BCMA and other targets such as CD38 and GPRC5D are not ubiquitously expressed on MM cells, with reports of disease relapse presenting a significant challenge in patient trials.